AstraZeneca
FDA grants breakthrough status to T-DXd for two HER2-positive cancers
Daiichi Sankyo and AstraZeneca have garnered FDA Breakthrough Therapy Designations (BTDs) for their Enhertu (T-DXd) therapy to treat two distinct ...
Unveiling the Intricate Symphony: AstraZeneca’s Farxiga at the Heart of Cardiorenal Insights
In the heart of Amsterdam, amidst the captivating backdrop of the European Society of Cardiology (ESC) scientific sessions, AstraZeneca wielded ...
Legal Skirmishes Erupt as AstraZeneca Delves into Battle Over Drug Pricing Reforms with IRA
As the clock ticks down to the eagerly awaited unveiling of the Centers for Medicare and Medicaid Services’ (CMS) list ...
Horizon Surpasses Roche in Rare Disease Reputation, While Pfizer’s Standing Declines
Horizon Therapeutics continues to collect accolades as it progresses toward its acquisition, with rare disease organizations now recognizing its excellence. ...
FDA Issues Warning Letter to AstraZeneca Regarding ‘Misleading’ Breztri Efficacy Claims
AstraZeneca’s promotional campaign for Breztri Aerosphere, a treatment for chronic obstructive pulmonary disease (COPD), has encountered significant regulatory turbulence, with ...
Twitter and BioNTech under fire for evading COVID-19 vaccine questions
The regulatory organization overseeing the German communications sector has accused BioNTech of attempting to evade a public discussion regarding vaccine ...
Daiichi Sankyo to Dominate Antibody-Drug Conjugates Market by 2029
Daiichi has successfully established ADCs (Antibody-Drug Conjugates) as a significant therapeutic approach, overcoming previous years of underwhelming results. Even though ...
Checkpoint inhibitor patent challenges are settled by AZ and BMS
AstraZeneca has announced the resolution of three lawsuits filed against it by Bristol-Myers Squibb (BMS) and Ono Pharma, alleging patent ...
Blockbuster Cancer Immunotherapy Showdown Ends: Bristol Myers Squibb and AstraZeneca Settle Patents Clash
Bristol Myers Squibb (BMS) and AstraZeneca have quickly resolved patent infringement lawsuits related to their cancer immunotherapies. The companies reached ...
AstraZeneca Expects Higher China Sales, Denies Spinoff Report
AstraZeneca’s CEO Pascal Soriot has denied a report that the company is considering spinning off its China business, which is ...
Enhertu increases survival in solid tumors with HER2+
AstraZeneca and Daiichi Sankyo have received a boost in their efforts to gain approval for Enhertu as a therapy for ...
Sharon Barr is appointed executive vice president of biopharmaceuticals R&D by AstraZeneca
Source – AstraZeneca AstraZeneca has made a significant leadership announcement, appointing Sharon Barr as the new Executive Vice President for ...
The UK is looking into GLP-1 medications made by Novo Nordisk, AstraZeneca, Lilly, and Sanofi for GLP-1 inhibitor suicide risk
Following the European Union’s lead, the United Kingdom has initiated an investigation into the potential suicide risks associated with popular ...
A New Hope for Children and Teens with gMG: Soliris Gets EU Approval
Source – AstraZeneca The European Union (EU) has granted approval for the expanded use of Soliris (eculizumab) to treat refractory ...
Jardiance Receives EU Approval for Treating Chronic Kidney Disease (CKD), Posing a Strong Challenge to Forxiga
Source – Boehringer Ingelheim The European Union has granted approval for Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor, Jardiance (empagliflozin), ...
Powerful Alliance: AstraZeneca Teams Up with SK Chemicals to Revolutionize Diabetes Treatment with Sidapvia Combo Drug
Korea’s SK Chemicals has recently entered into an agreement with AstraZeneca to manufacture the diabetes drug Sidapvia for the remainder ...
Pieris Takes Drastic Measures Following AstraZeneca Partnership Loss for Elarekibep
Source – Pieris Pharmaceuticals AstraZeneca has ended its collaboration with Pieris Pharmaceuticals on the respiratory drug candidate elarekibep, leading Pieris ...
FDA has approved Beyfortus as a treatment for RSV illness in newborns
Source – Sanofi On July 17, 2023 Sanofi and AstraZeneca received approval from the US Food and Drug Administration (FDA) ...
Enhertu Receives Approval in China as Groundbreaking HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer Patients
Source – AstraZeneca Enhertu (trastuzumab deruxtecan), a targeted antibody drug conjugate developed by AstraZeneca and Daiichi Sankyo, has received approval ...
DATOPOTAMAB DERUXTECAN MEETS DUAL PRIMARY ENDPOINT IN TROPION-LUNG01 PHASE III TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER
On July 3, 2023, AstraZeneca presented encouraging top-line results from the TROPION-Lung01 Phase III trial that demonstrated the positive efficacy ...
Imfinzi + Imjudo: Unprecedented 4-Year Survival in Advanced Liver Cancer
Source – AstraZeneca On 29 June 2023, new findings from the HIMALAYA Phase III trial revealed that AstraZeneca’s Imfinzi (durvalumab) ...
AstraZeneca Invests $400M in Reforestation and Biodiversity
Source – AstraZeneca AstraZeneca has made a significant announcement of a $400 million investment in its global AZ Forest program, ...
Xigduo XR Receives Approval in China for the Treatment of Type II Diabetes in Adults
Source – AstraZeneca On June 27, 2023, AstraZeneca’s Xigduo XR, a once-daily fixed-dose combination of dapagliflozin and metformin hydrochloride extended-release, ...
Addressing Low Diagnosis Rates for Kidney Disease: The Urgent Need for Better Screening, as Highlighted by AstraZeneca
How AstraZeneca’s Research Shows the Need for Improved Screening Methods to Tackle Low Diagnosis Rates for Kidney Disease AstraZeneca, the ...
Significant Surge in Biologic Medications for Lupus Treatment as Rheumatologists Shift Away from Traditional Off-Label Therapies
A recent analysis conducted by Spherix Global Insights reveals a notable increase in the utilization of new biologic drugs, namely ...
In the US, patients with advanced HR-positive breast cancer are given priority review for the combination of capivasertib and Faslodex
Source- Astrazeneca The US Food and Drug Administration (FDA) has accepted and granted Priority Review to AstraZeneca’s New Drug Application ...
For the treatment of people with refractory generalized myasthenia gravis, Soliris has received approval in China
Source- Astrazeneca For the treatment of adult patients with refractory generalized myasthenia gravis (gMG) and anti-acetylcholine receptor (AChR) antibody positivity, ...
FDA Advisory Committee Unanimously Recommends Nirsevimab for Preventing RSV Lower Respiratory Tract Disease in Infants
Source: AstraZeneca The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously, with a 21 to 0 decision, affirming the ...
Danicopan Shows Promise as an Add-On to Ultomiris or Soliris, Enhancing Hemoglobin Levels and Disease Control in PNH Patients
Source – AstraZeneca Promising outcomes emerged from the pivotal Phase III ALPHA trial, revealing that danicopan, an investigational oral Factor ...
AstraZeneca Enters $2 Billion Deal with Quell for Treg Cell Therapy
British start-up Quell Therapeutics has secured a collaboration with AstraZeneca focused on cell therapies for autoimmune diseases, with an upfront ...
